Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid

Luis Concha-Marambio, Sandra Pritzkow, Mohammad Shahnawaz, Carly M. Farris, Claudio Soto

Published: 2023-01-17 DOI: 10.1038/s41596-022-00787-3

alpha-synuclein aggregates

Seed amplification

Parkinson''s disease

synucleinopathies

biochemical diagnosis

AI 解读

Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail

Profiling native pulmonary basement membrane stiffness using atomic force microscopy

Genetic circuit design automation with Cello 2.0

Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages

Scalable dual-omics profiling with single-nucleus chromatin accessibility and mRNA expression sequencing 2 (SNARE-seq2)

A practical guide to scanning light-field microscopy with digital adaptive optics

Effective high-throughput isolation of fully human antibodies targeting infectious pathogens

Improved sampling and DNA extraction procedures for microbiome analysis in food-processing environments

MOF-derived nanoporous carbons with diverse tunable nanoarchitectures

Tutorial: a statistical genetics guide to identifying HLA alleles driving complex disease

查看全部

Sections

Figures

References

Misfolded alpha-synuclein (αSyn) aggregates are a hallmark event in Parkinson’s disease (PD) and other synucleinopathies. Recently, αSyn seed amplification assays (αSyn-SAAs) have shown promise as a test for biochemical diagnosis of synucleinopath
Introduction
Materials
Procedure
- Procedure 1: original αSyn-SAA
- Procedure 2: optimized αSyn-SAA
Troubleshooting
Timing
Anticipated results
References
ACKNOWLEDGMENTS

Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998).
Sulzer, D. & Edwards, R. H. The physiological role of α-synuclein and its relationship to Parkinson’s Disease. J. Neurochem. 150, 475–486 (2019).
Mehra, S., Sahay, S. & Maji, S. K. α-Synuclein misfolding and aggregation: implications in Parkinson’s disease pathogenesis. Biochim. Biophys. Acta Proteins Proteom. 1867, 890–908 (2019).
Steiner, J. A., Quansah, E. & Brundin, P. The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res. 373, 161–173 (2018).
Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95, 13363–13383 (1998).
Moda, F. et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N. Engl. J. Med. 371, 530–539 (2014).
Concha-Marambio, L. et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med. 8, 370ra183 (2016).
Concha-Marambio, L., Chacon, M. A. & Soto, C. Preclinical detection of prions in blood of nonhuman primates infected with variant Creutzfeldt-Jakob disease. Emerg. Infect. Dis. 26, 34–43 (2020).
Fiorini, M. et al. High diagnostic accuracy of RT-QuIC assay in a prospective study of patients with suspected sCJD. Int. J. Mol. Sci. 21, 880 (2020).
Orrú, C. D. et al. Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid. mBio 6, e02451-14 (2015).
Orrú, C. D. et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N. Engl. J. Med. 371, 519–529 (2014).
Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812–818 (2016).
Shahnawaz, M. et al. Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163–172 (2017).
Groveman, B. R. et al. Extended and direct evaluation of RT-QuIC assays for Creutzfeldt-Jakob disease diagnosis. Ann. Clin. Transl. Neurol. 4, 139–144 (2017).
Concha-Marambio, L. et al. Seed amplification assay to diagnose early Parkinson’s and predict dopaminergic deficit progression. Mov. Disord. 36, 2444–2446 (2021).
Russo, M. J. et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathol. Commun. 9, 179 (2021).
Ferreira, N. D. C. & Caughey, B. Proteopathic seed amplification assays for neurodegenerative disorders. Clin. Lab. Med. 40, 257–270 (2020).
Kang, U. J. et al. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson’s disease. Mov. Disord. 34, 536–544 (2019).
Concha-Marambio, L., Shahnawaz, M. & Soto, C. Detection of misfolded α-synuclein aggregates in cerebrospinal fluid by the protein misfolding cyclic amplification platform. Methods Mol. Biol. 1948, 35–44 (2019).
Shahnawaz, M. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578, 273–277 (2020).
Soto, C. & Pritzkow, S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 21, 1332–1340 (2018).
Narayanan, A. et al. A first order phase transition mechanism underlies protein aggregation in mammalian cells. Elife 8, 1–26 (2019).
Kocisko, D. A. et al. Cell-free formation of protease-resistant prion protein. Nature 370, 471–474 (1994).
Jarrett, J. T. & Lansbury, P. T. Seeding ‘one-dimensional crystallization’ of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73, 1055–1058 (1993).
Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810–813 (2001).
Saá, P., Castilla, J. & Soto, C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J. Biol. Chem. 281, 35245–35252 (2006).
Castilla, J., Saá, P. & Soto, C. Detection of prions in blood. Nat. Med. 11, 982–985 (2005).
Saá, P., Castilla, J. & Soto, C. Presymptomatic detection of prions in blood. Science 313, 92–94 (2006).
Bougard, D. et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med. 8, 370ra182 (2016).
Atarashi, R. et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat. Methods 4, 645–650 (2007).
Atarashi, R. et al. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat. Methods 5, 211–212 (2008).
Atarashi, R. et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med. 17, 175–178 (2011).
Pujols, J. et al. High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors. Int. J. Mol. Sci. 18, 478 (2017).
Kurnik, M. et al. Potent α-synuclein aggregation inhibitors, identified by high-throughput screening, mainly target the monomeric state. Cell Chem. Biol. 25, 1389–1402.e9 (2018).
Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).
Parnetti, L. et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 18, 573–586 (2019).
Chen-Plotkin, A. S. et al. Finding useful biomarkers for Parkinson’s disease. Sci. Transl. Med. 10, eaam6003 (2018).
Emamzadeh, F. N. & Surguchov, A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front. Neurosci. 12, 612 (2018).
Sharma, S. et al. Biomarkers in Parkinson’s disease (recent update). Neurochem. Int. 63, 201–229 (2013).
Atik, A., Stewart, T. & Zhang, J. Alpha-synuclein as a biomarker for Parkinson’s disease. Brain Pathol. 26, 410–418 (2016).
Gao, L. et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci. 125, 645–654 (2015).
Ganguly, U. et al. Alpha-synuclein as a biomarker of Parkinson’s disease: good, but not good enough. Front. Aging Neurosci. 13, 702639 (2021).
Mollenhauer, B. et al. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid—method comparison and round robin study. J. Neurochem. 149, 126–138 (2019).
Ohrfelt, A. et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders—a marker of synapse loss? Neurosci. Lett. 450, 332–335 (2009).
Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164 (2002).
Eusebi, P. et al. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis. Mov. Disord. 32, 1389–1400 (2017).
Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571–576 (2000).
Ingelsson, M. Alpha-synuclein oligomers—neurotoxic molecules in Parkinson’s disease and other Lewy body disorders. Front. Neurosci. 10, 408 (2016).
Tokuda, T. et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766–1772 (2010).
Hansson, O. et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res. Ther. 6, 25 (2014).
Majbour, N. K. et al. Cerebrospinal α-synuclein oligomers reflect disease motor severity in DeNoPa Longitudinal Cohort. Mov. Disord. 36, 2048–2056 (2021).
Han, J.-Y., Jang, H.-S., Green, A. J. E. & Choi, Y. P. RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy Body patients and of a transgenic mouse model of synucleinopathy. Prion 14, 88–94 (2020).
Manne, S. et al. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson’s disease patients. Mov. Disord. 35, 268–278 (2020).
Bongianni, M. et al. α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann. Clin. Transl. Neurol. 6, 2120–2126 (2019).
Han, J.-Y., Shin, C. & Choi, Y. P. Preclinical detection of alpha-synuclein seeding activity in the colon of a transgenic mouse model of synucleinopathy by RT-QuIC. Viruses 13, 759 (2021).
Bargar, C. et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 62 (2021).
Iranzo, A. et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 20, 203–212 (2021).
De Luca, C. M. G. et al. Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy. Transl. Neurodegener. 8, 24 (2019).
Perra, D. et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. 3, 1–11 (2021).
Stefani, A. et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain 144, 1118–1126 (2021).
Singer, W. et al. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy Body synucleinopathies. Ann. Neurol. 88, 503–512 (2020).
Wang, Z. et al. Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 78, 1–11 (2020).
Jung, B. C. et al. Amplification of distinct α-synuclein fibril conformers through protein misfolding cyclic amplification. Exp. Mol. Med. 49, e314 (2017).
Fenyi, A. et al. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification. Neurobiol. Dis. 129, 38–43 (2019).
Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49–62 (2020).
Park, S.-J. et al. Establishment of method for the determination of aggregated α-synuclein in DLB patient using RT-QuIC assay. Protein Pept. Lett. 28, 115–120 (2021).
Kakuda, K. et al. Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid. Sci. Rep. 9, 6001 (2019).
Singer, W. et al. Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann. Neurol. 89, 1212–1220 (2021).
Masuda, M. et al. Cysteine misincorporation in bacterially expressed human α-synuclein. FEBS Lett. 580, 1775–1779 (2006).

Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid

推荐阅读